Atsushi Ogata

ORCID: 0000-0003-3944-3442
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Laser-Plasma Interactions and Diagnostics
  • Laser-induced spectroscopy and plasma
  • Magnetic confinement fusion research
  • Particle Accelerators and Free-Electron Lasers
  • Rheumatoid Arthritis Research and Therapies
  • Particle accelerators and beam dynamics
  • Multiple Myeloma Research and Treatments
  • Laser-Matter Interactions and Applications
  • Systemic Lupus Erythematosus Research
  • Gyrotron and Vacuum Electronics Research
  • Autoimmune and Inflammatory Disorders Research
  • Plasma Diagnostics and Applications
  • Laser Design and Applications
  • Cytokine Signaling Pathways and Interactions
  • Monoclonal and Polyclonal Antibodies Research
  • Systemic Sclerosis and Related Diseases
  • Advanced X-ray Imaging Techniques
  • Atomic and Molecular Physics
  • Superconducting Materials and Applications
  • Terahertz technology and applications
  • Immunotherapy and Immune Responses
  • High-pressure geophysics and materials
  • Spondyloarthritis Studies and Treatments
  • Photocathodes and Microchannel Plates
  • Plasma Applications and Diagnostics

Osaka University
2012-2021

Osaka Police Hospital
2019-2021

Osaka Hospital
2015-2019

NTT WEST Osaka Hospital
2016-2019

Takeda (Japan)
2015

National Hospital Organization
2015

Tohoku University Hospital
2015

Saitama Medical University
2015

Hamamatsu University School of Medicine
2015

Osaka City University
2015

Abstract IL-6 mediates growth of some human multiple myeloma (MM) cells and IL-6-dependent cell lines. Although three signaling pathways (STAT1, STAT3, Ras-dependent MAPK cascade) have been reported, cascades mediating IL-6-triggered MM lines are not defined. In this study, we therefore characterized in lines, patient cells, B9 to determine which pathway growth. induced phosphorylation JAK kinases gp130, regardless the proliferative response factor. Accordingly, next examined downstream via...

10.4049/jimmunol.159.5.2212 article EN The Journal of Immunology 1997-09-01

The causality and pathogenic mechanism of microbiome composition remain elusive in many diseases, including autoimmune diseases such as rheumatoid arthritis (RA). This study aimed to elucidate gut microbiome's role RA pathology by a comprehensive metagenome-wide association (MWAS).We conducted MWAS the Japanese population (ncase=82, ncontrol=42) using whole-genome shotgun sequencing high depth (average 13 Gb per sample). Our consisted three major bioinformatic analytic pipelines...

10.1136/annrheumdis-2019-215743 article EN cc-by-nc Annals of the Rheumatic Diseases 2019-11-07

A laser pulse with a power of $\ensuremath{\sim}3$ TW and duration 1 ps has been focused onto gas. Ultrahigh-gradient electron acceleration observed in the laser-produced plasma density $\ensuremath{\sim}{10}^{19}$ c${\mathrm{m}}^{--3}$ when injecting MeV $/c$ electrons. The simulation laser-plasma interaction revealed existence ultrahigh-gradient wake fields excited due to self-modulation its acceleration, consistent experimental results.

10.1103/physrevlett.74.4428 article EN Physical Review Letters 1995-05-29

Background Hypoxic and ischemic stresses cause a series of well-documented changes in myocardial cells tissues, including loss contractility, lipid fatty acid metabolism, irreversible membrane damage leading to eventual cellular death. Activated neutrophils are considered be involved this injury. By stimulation the with chemotactic factors, canine can induced adhere isolated cardiac myocytes only if have been previously exposed cytokines such as tumor necrosis factor–α, interleukin (IL)-1,...

10.1161/01.cir.91.5.1520 article EN Circulation 1995-03-01

Objective. SSc is an autoimmune disease characterized by fibrosis of the skin and internal organs. Although aetiology remains uncertain, many reports have suggested that IL-6 involved in pathogenesis. Tocilizumab, anti-IL-6 receptor antibody, anti-arthritis medicine works through blockade functions. To examine effect tocilizumab on SSc, we administered to two patients. Methods. Two dcSSc patients were at 8 mg/kg once a month for 6 months. One patient had pulmonary assessed CT spirometry,...

10.1093/rheumatology/keq275 article EN cc-by-nc Lara D. Veeken 2010-09-05

<h3>Objective</h3> To identify a novel serum biomarker of disease activity in inflammatory autoimmune disorders. <h3>Methods</h3> Sera obtained from rheumatoid arthritis (RA) patients before and after anti-TNF therapy were analysed by iTRAQ (isobaric tags for relative absolute quantitation) quantitative proteomic analysis further validated ELISA. <h3>Results</h3> Of 326 proteins identified analysis, increased levels leucine-rich α-2 glycoprotein (LRG) was RA therapy. Serum LRG concentrations...

10.1136/ard.2009.118919 article EN Annals of the Rheumatic Diseases 2009-10-22

To evaluate the efficacious noninferiority of subcutaneous tocilizumab injection (TCZ-SC) monotherapy to intravenous TCZ infusion (TCZ-IV) in Japanese patients with rheumatoid arthritis (RA) an inadequate response synthetic and/or biologic disease-modifying antirheumatic drugs (DMARDs).This study had a double-blind, parallel-group, double-dummy, comparative phase III design. Patients were randomized receive TCZ-SC 162 mg every 2 weeks or TCZ-IV 8 mg/kg 4 weeks; no DMARDs allowed during...

10.1002/acr.22110 article EN Arthritis Care & Research 2013-08-27

Objective Subcutaneous (SC) and intravenous formulations of tocilizumab (TCZ) are available for the treatment patients with rheumatoid arthritis (RA), based on efficacy safety observed in clinical trials. Anti-TCZ antibody development its impact were evaluated adult RA treated TCZ (TCZ-IV) or TCZ-SC as monotherapy combination conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Methods Data from 5 8 TCZ-IV phase III trials 1 pharmacology study (&gt;50 000 samples) pooled...

10.1136/annrheumdis-2016-210297 article EN cc-by-nc Annals of the Rheumatic Diseases 2016-12-22

We analyzed the stimulatory effect of oncostatin M (OSM), leukemia inhibitory factor (LIF), interleukin 6 (IL-6), IL-11, and anti-IL-6 antibody (Ab), receptor monoclonal (mAb), anti-gp130 mAb on growth human plasmacytoma cells freshly isolated from a patient with multiple myeloma. The purified showed plasmacytoid morphology expressed CD38, CD54, CD56 antigens but no CD3, CD5, CD10, CD19, CD20, or very late antigen 5. IL-6 (IL-6R) its signal transducer, gp130, were their cell surface at low...

10.1084/jem.179.4.1343 article EN The Journal of Experimental Medicine 1994-04-01

A 47-year-old female patient with Behçet's disease had been treated colchicine, prednisolone, cyclosporine A, and infliximab. Because she relapsed, however, treatment tocilizumab, a humanized anti-interleukin 6 receptor antibody, was started. This suppressed the patient's clinical manifestations, including ocular attacks, for 1 year improved her visual acuity. experience indicates that tocilizumab may constitute therapeutic option refractory disease.

10.1007/s10165-011-0497-5 article EN Modern Rheumatology 2011-07-11

Semaphorin 4D (Sema4D)/CD100 has pleiotropic roles in immune activation, angiogenesis, bone metabolism, and neural development. We undertook this study to investigate the role of Sema4D rheumatoid arthritis (RA).Soluble (sSema4D) levels serum synovial fluid were analyzed by enzyme-linked immunosorbent assay. Cell surface expression transcripts peripheral blood cells from RA patients, immunohistochemical staining was performed synovium. Generation sSema4D evaluated an ADAMTS-4-treated...

10.1002/art.39086 article EN cc-by-nc-nd Arthritis & Rheumatology 2015-02-23
Coming Soon ...